Oseltamivir treatment of mice before or after mild influenza infection reduced cellular and cytokine inflammation in the lung

Influenza and other Respiratory Viruses

Volumn 5, Issue 5, 2011, Pages 343-350

  Wong, Zi Xin ^a   Jones, Jessica E ^a   Anderson, Gary P ^a   Gualano, Rosa C ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cytokine; Inflammation; Influenza; Leukocyte; Oseltamivir

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; KERATINOCYTE DERIVED CHEMOKINE; MONOCYTE CHEMOTACTIC PROTEIN 1; OSELTAMIVIR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; INFLAMMATORY CELL; INFLUENZA; INFLUENZA A; INFLUENZA A (H3N1); LUNG LAVAGE; MACROPHAGE; MOUSE; NEUTROPHIL; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; LUNG; MALE; MICE; MICE, INBRED BALB C; OSELTAMIVIR; TREATMENT OUTCOME;

EID: 79960424606     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/j.1750-2659.2011.00235.x     Document Type: Article

References (30)

1. Ward P, Small I, Smith J, Suter P, Dutkowski R. Oseltamivir (Tamiflu(R)) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 2005; 55(Suppl 1):i5-i21.
2. Heinonen S, Silvennoinen H, Lehtinen P et al. Early oseltamivir treatment of influenza in children 1-3years of age: a randomized controlled trial. Clin Infect Dis 2010; 51:887-894.
3. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005; 353:1363-1373.
4. Yen HL, Monto AS, Webster RG, Govorkova EA. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J Infect Dis 2005; 192:665-672.
5. Liu Z, Guo Z, Wang G et al. Evaluation of the efficacy and safety of a statin/caffeine combination against H5N1, H3N2 and H1N1 virus infection in BALB/c mice. Eur J Pharm Sci 2009; 38:215-223.
6. Smee DF, Wong MH, Bailey KW, Sidwell RW. Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A (H1N1) and B viruses. Antivir Chem Chemother 2006; 17:185-192.
7. Burger RA, Billingsley JL, Huffman JH et al. Immunological effects of the orally administered neuraminidase inhibitor oseltamivir in influenza virus-infected and uninfected mice. Immunopharmacology 2000; 47:45-52.
8. Clark IA, Alleva LM, Budd AC, Cowden WB. Understanding the role of inflammatory cytokines in malaria and related diseases. Travel Med Infect Dis 2008; 2:67-81.
9. Fritz RS, Hayden FG, Calfee DP et al. Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment. J Infect Dis 1999; 180:586-593.
10. Hayden FG, Fritz RS, Lobo MC et al. Local and systemic cytokine responses during experimental human influenza A virus infection: relation to symptom formation and host defense. J Clin Invest 1998; 101:643-649.
11. La Gruta NL, Kedzierska K, Stambas J, Doherty PC. A question of self-preservation: immunopathology in influenza virus infection. Immunol Cell Biol 2007; 85:85-92.
12. Holt PG, Strickland DH, Wikstrom ME, Jahnsen FL. Regulation of immunological homeostasis in the respiratory tract. Nat Rev Immunol 2008; 8:142-152.
13. Fedson DS. Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents: why they are needed and how they might work. Influenza Other Respi Viruses 2009; 3:129-142.
14. Reading PC, Morey LS, Crouch EC, Anders EM. Collectin-mediated antiviral host defense of the lung: evidence from influenza virus infection of mice. J Virol 1997; 71:8204-8212.
15. Gualano RC, Hansen MJ, Vlahos R et al. Cigarette smoke worsens lung inflammation and impairs resolution of influenza infection in mice. Respir Res 2008; 9:53.
16. Upfal J. The Australian Drug Guide, 7th edn. Melbourne: Black Inc., 2007.
17. Govorkova EA, Ilyushina NA, McClaren JL et al. Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. Antimicrob Agents Chemother 2009; 53:3088-3096.
18. Vlahos R, Bozinovski S, Jones JE et al. Differential protease, innate immunity, and NF-kappaB induction profiles during lung inflammation induced by subchronic cigarette smoke exposure in mice. Am J Physiol Lung Cell Mol Physiol 2006; 290:L931-L945.
19. Lew M. Good statistical practice in pharmacology problem 1. Br J Pharmacol 2007; 152:295-298.
20. Kaiser L, Fritz RS, Straus SE, Gubareva L, Hayden FG. Symptom pathogenesis during acute influenza: interleukin-6 and other cytokine responses. J Med Virol 2001; 64:262-268.
21. Lee N, Chan PK, Hui DS et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 2009; 200:492-500.
22. Govorkova EA, Ilyushina NA, Boltz DA et al. Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob Agents Chemother 2007; 51:1414-1424.
23. Moore ML, Chi MH, Zhou W et al. Cutting Edge: Oseltamivir decreases T cell GM1 expression and inhibits clearance of respiratory syncytial virus: potential role of endogenous sialidase in antiviral immunity. J Immunol 2007; 178:2651-2654.
24. Janeway CAJ, Travers P, Walport M, Shlomchik MJ. Immunobiology: The Immune System in Health and Disease, 6th edn. New York: Garland Science Publishing, 2005.
25. Ibelgaufts H. COPE: Cytokines & Cells Online Pathfinder Encyclopedia. 2010[updated 2010; cited]; Available from: (Accessed 5 November 2010).
26. Bot A, Bot S, Bona CA. Protective role of gamma interferon during the recall response to influenza virus. J Virol 1998; 72:6637-6645.
27. Price GE, Gaszewska-Mastarlarz A, Moskophidis D. The role of alpha/beta and gamma interferons in development of immunity to influenza A virus in mice. J Virol 2000; 74:3996-4003.
28. Nguyen HH, van Ginkel FW, Vu HL et al. Gamma interferon is not required for mucosal cytotoxic T-lymphocyte responses or heterosubtypic immunity to influenza A virus infection in mice. J Virol 2000; 74:5495-5501.
29. Graham MB, Dalton DK, Giltinan D et al. Response to influenza infection in mice with a targeted disruption in the interferon gamma gene. J Exp Med 1993; 178:1725-1732.
30. Hayden FG, Treanor JJ, Fritz RS et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999; 282:1240-1246.